DTC-and-Me: Patient, Provider, Proteins and Regulators
The yet-unrealized potential for more “personalized” Direct-to-Consumer (DTC) tests to fundamentally alter the practice and economics of healthcare is undeniable. However, there are also many challenges to be met, including the herculean task of ensuring that the information provided by such tests i...
Main Authors: | Fintan R. Steele, Larry Gold |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2014-03-01
|
Series: | Journal of Personalized Medicine |
Subjects: | |
Online Access: | http://www.mdpi.com/2075-4426/4/1/79 |
Similar Items
-
Slow Off-Rate Modified Aptamer (SOMAmer) Proteomic Analysis of Patient-Derived Malignant Glioma Identifies Distinct Cellular Proteomes
by: Thatchawan Thanasupawat, et al.
Published: (2021-09-01) -
Cross-sectional proteomic expression in Parkinson's disease-related proteins in drug-naïve patients vs healthy controls with longitudinal clinical follow-up
by: Ilham Yahya Abdi, et al.
Published: (2023-02-01) -
Identification of serum biomarkers for necrotizing enterocolitis using aptamer-based proteomics
by: Stephen Mackay, et al.
Published: (2023-05-01) -
The application of Aptamer in biomarker discovery
by: Yongshu Li, et al.
Published: (2023-07-01) -
High-Multiplex Aptamer-Based Serum Proteomics to Identify Candidate Serum Biomarkers of Oral Squamous Cell Carcinoma
by: Sebastian Blatt, et al.
Published: (2023-03-01)